The Fortune 500 pharma giant will sequence the exomes of 10 million people, with the goal of developing new therapies and ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment ...

NEW YORK (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals, Illumina and 17 U.S ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating ...

NEW YORK, NY / ACCESSNEWSWIRE / January 20, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of ...

Regeneron Pharmaceuticals Inc. closed 42.77% short of its 52-week high of $1,211.20, which the company achieved on August ...

Regeneron Pharmaceuticals Inc. closed 41.92% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.